Sign in
Not yet recruitingPhase 1/2

SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection

Key facts

Who runs it
Shenzhen Geno-Immune Medical Institute
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
10 people, planned
Starts
30 Jun 2027
Expected to end
31 Dec 2029
Type of study
Interventional
Treatments tested
  • Direct intravenous injection of ivlv-X1 lentiviral vector
Record updated
3 November 2026

Who can take part

Age
1 month to 1 year
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Diagnosis of SCID-X1 based on:; A proven mutation in the common interleukin-2 receptor gamma chain gene as defined by direct sequencing of patient DNA; T-cell immune deficiency defined as one or more of the following: CD3+ autologous T cells < 300/ul, or less than 50% of normal value for in vitro mitogen stimulation, or absent proliferation in vitro to antigen stimulation
  • No available HLA identical related donor
  • With severe infections, including but not limited to: pneumonitis; protracted diarrhea requiring total parenteral nutrition; infection with herpes viruses or adenovirus; disseminated BCG infection
  • No cytogenetic abnormalities (medullary karyotype) and no detection of main rearrangements associated with acute leukemia
  • No prior allogeneic stem cell transplantation
  • Life expectancy ≥ 3 months
  • Documented to be negative for HIV infection
  • Written, informed consent obtained prior to any study-specific procedures

Who cannot take part

  • Current treatment with any chemotherapeutic agent (becomes eligible if not on treatment for at least 1 month)
  • Current treatment with any immunosuppressive agent, excluding corticosteroids
  • Diagnosis of active malignant disease other than EBV-associated lymphoproliferative disease
  • Patients with evidence of infection with HIV-1 or 2
  • Presence of a medical condition indicating that survival will be less than 4 weeks such as the requirement for mechanical ventilation, severe failure of a major organ system, or evidence of a serious, progressive infection that is refractory to medical treatment
  • No available molecular diagnosis confirming SCID-X1
  • Existence of an available HLA-identical related donor
  • Patients, in the opinion of investigators, may not be eligible or not able to comply with the study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a Phase I/II gene therapy trial treating X-linked severe combined immunodeficiency (SCID-X1) using a self-inactivating lentiviral vector (ivlv-X1) to functionally correct the genetic defect. The primary objectives are to evaluate the safety and efficacy of the direct intravenous lentiviral gene transfer protocol.

The group in the trial

  • Single armTreatment being tested

    In vivo LV gene transfer to treat SCID-X1

    Treatment: Direct intravenous injection of ivlv-X1 lentiviral vector

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1) Via Direct Intravenous Injection of Lentiviral Vector (Ivlv-X1)
Record updated
3 November 2026